Baxter Says Anticipates Restarting Highest-Throughput IV Solutions Manufacturing Line Within Next Week; FDA Authorized Temporary Importation For Variety Of Product Codes From 2 Additional Baxter Manufacturing Facilities, In Thailand & Singapore; Goal Remains To Return To 90% To 100% Allocation Of Some IV Solution Product Codes For U.S. Customers By 2024 End
Portfolio Pulse from Benzinga Newsdesk
Baxter plans to restart its highest-throughput IV solutions manufacturing line within a week. The FDA has authorized temporary importation from Baxter's facilities in Thailand and Singapore. The company aims to return to 90%-100% allocation of some IV solution product codes for U.S. customers by the end of 2024.
October 24, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baxter is set to restart its highest-throughput IV solutions line and has received FDA approval for temporary imports from Thailand and Singapore. The company aims to meet full allocation for U.S. customers by the end of 2024.
The news indicates a positive development for Baxter as it plans to restart a critical manufacturing line and has received FDA approval for temporary imports, which should help meet demand. This is likely to have a positive short-term impact on Baxter's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90